After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
PACB belongs to the Healthcare sector of the NASDAQ while operating in the Medical Devices industry. At the end of the last regular session, the stock closed at $6.88 and fluctuated between $7.10 as its day high and $6.61 as its day low. The current market capitalization of Pacific Biosciences of California Inc is $1.84B. A total of 7.08 million shares were traded on the day, compared to an average of 6.44M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, PACB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 7 BUYs and 14 SELLs from insiders. Insiders purchased 1,353,687 shares during that period but sold 231,517.
In the most recent transaction, Van Oene Mark sold 31,012 shares of PACB for 7.77 per share on Jan 09. After the transaction, the insider now owns 910,171 company shares. In a previous transaction on Dec 14, HENRY CHRISTIAN O sold 20,000 shares at 10.00 per share. PACB shares that the insider owns now total 1,086,095.
Among the insiders who sold shares, Kim Susan G. disposed of 19,257 shares on Sep 29 at a per-share price of $8.44. This resulted in the insider holding 306,085 shares of PACB after the transaction. In another insider transaction, HENRY CHRISTIAN O sold 96,844 shares at $10.12 per share on Sep 18. Company shares held by the insider now total 1,106,095.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for PACB in the last 3 months, the mean price target is $12.19 with high estimates of $19.00 and low estimates of $8.00. In terms of 52-week highs and lows, PACB has a high of $14.55 and a low of $5.74.
As of this writing, PACB has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.33. The company reported an EPS of -$0.28 in the last quarter, which was 12.50% higher than expectations of -$0.32.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. PACB’s latest balance sheet shows that the firm has $1.04B in Cash & Short Term Investments as of fiscal 2021. There were $955.36M in debt and $71.71M in liabilities at the time. Its Book Value Per Share was $2.96, while its Total Shareholder’s Equity was $790.99M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PACB is Buy with a score of 4.29.
